Net

BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones

Retrieved on: 
Monday, February 26, 2024
Human services, Inflation, AAAAI, Research, Investment, Growth, GAAP, HAE, Tranche, Webcast, Patient, Public expenditure, BioCryst Pharmaceuticals, Net, EPS, Workforce, American Academy, Pharmaceutical industry

RESEARCH TRIANGLE PARK, N.C., Feb. 26, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.

Key Points: 
  • The number of new ORLADEYO prescribers in the fourth quarter of 2023 (Q4 2023) was the largest number of new prescribers of any quarter in 2023.
  • The increase was primarily due to $90.9 million in ORLADEYO net revenue in the fourth quarter of 2023, compared to $70.7 million in the fourth quarter of 2022.
  • Revenue in the fourth quarter of 2023 also included $2.3 million of net revenue from RAPIVAB related sales, compared to $8.7 million in the fourth quarter of 2022.
  • Interest expense was $24.6 million in the fourth quarter of 2023, compared to $26.5 million in the fourth quarter of 2022.

Altus Group Reports Q4 and Fiscal 2023 Financial Results; Announces Quarterly Dividend Payment

Retrieved on: 
Thursday, February 22, 2024
Cloud, Intelligence, Free cash flow, Net, CRE, TSX, Analytics, Altus Group, Funding, Table, Adjustment, Earnings, Property tax, Revenue, EPS, Development, Environment, Retail

Consolidated Adjusted EBITDA* was $34.2 million, down 2.2% (3.4% on a Constant Currency basis).

Key Points: 
  • Consolidated Adjusted EBITDA* was $34.2 million, down 2.2% (3.4% on a Constant Currency basis).
  • Net cash provided by operating activities was $44.7 million, up 62.7%, and Free Cash Flow* was a record $40.1 million, up 109.3%.
  • Analytics revenues were $103.2 million, up 7.4% (6.1% on a Constant Currency basis), of which Recurring Revenue* was $93.0 million, up 8.4% (7.0% on a Constant Currency basis).
  • “2023 was a year of significant progress driving revenue, profit and free cash flow growth,” commented Jim Hannon, Chief Executive Officer of Altus Group.

Applied Optoelectronics Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Friday, February 23, 2024
Internet, Annual report, Risk, Table, Loss, CATV, GAAP, COVID-19, Webcast, Organization, FTTH, Security (finance), Net, EPS, Depreciation, Bank

“While our fourth quarter revenue came in below our expectations, our gross margin outperformed our projections, and we generated non-GAAP EPS at the high end of our guidance range.

Key Points: 
  • “While our fourth quarter revenue came in below our expectations, our gross margin outperformed our projections, and we generated non-GAAP EPS at the high end of our guidance range.
  • GAAP gross margin was 35.7%, compared with 10.1% in the fourth quarter of 2022 and 32.3% in the third quarter of 2023.
  • Non-GAAP gross margin was 36.4%, compared with 21.4% in the fourth quarter of 2022 and 32.5% in the third quarter of 2023.
  • Non-GAAP net income was $1.6 million, or $0.04 per diluted share, compared with non-GAAP net loss of $5.4 million, or $0.19 per basic share in the fourth quarter of 2022, and a non-GAAP net loss of $1.7 million, or $0.05 per basic share in the third quarter of 2023.

Plymouth Industrial REIT Reports Fourth Quarter Results

Retrieved on: 
Wednesday, February 21, 2024
Wells Fargo, Capital One, Investment, Growth, Table, Chase Bank, Sale, Tenant, NOI, Adjustment, IRR, GAAP, Acute and obtuse triangles, History, Public expenditure, Net, JPMorgan Chase, Holding company

BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Plymouth Industrial REIT , Inc. (NYSE: PLYM) (the “Company”) today announced its financial results for the fourth quarter and year ended December 31, 2023 and other recent developments.

Key Points: 
  • BOSTON, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Plymouth Industrial REIT , Inc. (NYSE: PLYM) (the “Company”) today announced its financial results for the fourth quarter and year ended December 31, 2023 and other recent developments.
  • During the fourth quarter, Plymouth completed the previously announced sale of its 156,634-square-foot industrial building in Marlton, New Jersey for $16.8 million.
  • During the fourth quarter, Plymouth delivered a fully leased industrial building in Jacksonville totaling 39,750 square feet.
  • During the fourth quarter, Plymouth also signed a seven-year, 108,000-square-foot lease at its 180,000-square-foot industrial building in Atlanta, bringing the new development to 100% occupancy.

Repligen Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, February 21, 2024
Acquisition, Filtration, Ultrafiltration, Growth, Loss, ESG, Cross-flow filtration, GAAP, Net, TFF, Repligen

WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023.

Key Points: 
  • WALTHAM, Mass., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2023, covering the three- and twelve-month periods ended December 31, 2023.
  • We are pleased to report that for the second quarter in a row, our book-to-bill ratio was above 1.0, at 1.03 for the fourth quarter.
  • Base revenue (non-GAAP) for Q4 2023 was $142.1 million, compared to $163.0 million for Q4 2022.
  • For Q4 2023, net loss (GAAP) was ($25.5) million, compared to net income (GAAP) of $48.7 million for Q4 2022.

WillScot Mobile Mini Reports Fourth Quarter 2023 and Full Year 2023 Results

Retrieved on: 
Tuesday, February 20, 2024
Net, Modularity, Debt, Capital expenditure, Sale, Net operating assets, Adjustment, Conference, Health, Net income, GAAP, Webcast, Tax, CAPEX, Bank statement, Depreciation, Bank

2 - Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow Margin, Net Debt to Adjusted EBITDA and Return on Invested Capital are non-GAAP financial measures.

Key Points: 
  • 2 - Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow Margin, Net Debt to Adjusted EBITDA and Return on Invested Capital are non-GAAP financial measures.
  • For comparability, we add back discontinued operations to reported revenue to calculate Free Cash Flow Margin.
  • WillScot Mobile Mini will host a conference call and webcast to discuss its fourth quarter 2023 results and 2024 outlook at 5:30 p.m. Eastern Time on Tuesday, February 20, 2024.
  • Choose "Events" and select the information pertaining to the WillScot Mobile Mini Holdings Fourth Quarter 2023 Conference Call.

Owlet Announces Fourth Quarter and Fiscal Year 2023 Results

Retrieved on: 
Thursday, March 7, 2024
Apps, Applications, Mobile, Wireless, Technology, Parenting, Baby, Maternity, Specialty, Software, Consumer, Retail, Consumer Electronics, Operating cost, OWLT, FDA, Adjustment, Entrepreneurship, Babysitting, Infant, Net, FY, Cryptocurrency

Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • Owlet , Inc. (“Owlet” or the “Company”) (NYSE:OWLT), the pioneer of smart infant monitoring, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023.
  • I’m proud of the immense progress our team has made in re-shaping the Company in 2023, and I look forward to continued successes in 2024.”
    Financial Results for the Fourth Quarter and Fiscal Year Ended December 31, 2023
    Revenues for the fourth quarter of 2023 were approximately $21.0 million.
  • Adjusted EBITDA loss was approximately $0.7 million for the fourth quarter of 2023, compared to $15.2 million for the fourth quarter of 2022.
  • Net loss per share was $0.97 for the fourth quarter of 2023, compared to net loss per share of $2.43 for the fourth quarter of 2022.

Akili Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, February 29, 2024
Biotechnology, Technology, FDA, Health, Pharmaceutical, Neurology, Mental Health, Health Technology, Medical Devices, Apps, Applications, Software, Therapy, Acquisition, Shionogi, Investment, Marketing, Variable, Quality of life, Growth, Coronavirus, Table, Food, Sale, Prevalence, Frustration, ARPU, GAAP, COVID-19, Welfare, DSM-IV codes, Patient, Policy, Clinical trial, Net, ADHD, Workforce, Ageing, Prescription, Pharmaceutical industry

Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2023, and provided an update on business progress.

Key Points: 
  • Akili, Inc. (Nasdaq: AKLI), a leading digital medicine company, today reported its financial results for the quarter and full year ended December 31, 2023, and provided an update on business progress.
  • Revenues: Total revenues for the fourth quarter of 2023 were $749 thousand compared to $702 thousand for the third quarter of 2023, driven by the continued growth of EndeavorOTC in the adult ADHD market in the fourth quarter.
  • Net Loss: GAAP net loss was $11.1 million for the fourth quarter of 2023, compared to a GAAP net loss of $15.9 million for the third quarter of 2023.
  • Non-GAAP net loss was $10.8 million for the fourth quarter of 2023, compared to a non-GAAP net loss of $13.9 million for the third quarter of 2023.

Annual Report 2023: LEO Pharma Delivers 10% Revenue Growth and Returns to Positive EBITDA

Retrieved on: 
Thursday, February 29, 2024
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Acquisition, EMA, Dermatology, DKK, Investment, CER, Growth, Research and development, Business development, Skin, Delgocitinib, Net, Risk, Development, LEO, Movement, Leo Pharma, Pharmaceutical industry

LEO Pharma delivers a solid operational performance uplift with double-digit revenue growth and an EBITDA uplift of DKK 2.1 billion, corresponding to a 20%-points margin improvement.

Key Points: 
  • LEO Pharma delivers a solid operational performance uplift with double-digit revenue growth and an EBITDA uplift of DKK 2.1 billion, corresponding to a 20%-points margin improvement.
  • LEO Pharma exceeded our profitability guidance and hit the upper range of our revenue growth guidance provided in March 2023.
  • LEO Pharma delivered 11.4 billion in revenue, corresponding to 7% revenue growth in 2023.
  • LEO Pharma exceeded our profitability guidance and hit the upper range of our revenue growth guidance provided in March 2023.

Pacific Coast Oil Trust Announces There Will Be No February Cash Distribution

Retrieved on: 
Thursday, February 29, 2024
Banking, Energy, Professional Services, Oil, Gas, Hearing, Report, Net, Accounting Standards Codification, Sale, Phillips 66, Consultant, Federal district, Bank statement, Barrel (unit), ARO, Special, Moss Adams, Marketing, Bank, Transport, Connection, Prejudice, Trustee, Dissolution, United States district court, Security (finance), Conveyance, State, Panel, Court, Retirement, Calendar, Face, County, Business analyst, Annual report, Evergreen, Letter, COVID-19, Hand, Motion, Internet, Superior court, Life insurance

The net profits deficit must be recouped from proceeds otherwise payable to the Trust from the Net Profits Interests.

Key Points: 
  • The net profits deficit must be recouped from proceeds otherwise payable to the Trust from the Net Profits Interests.
  • Pacific Coast Oil Trust is a Delaware statutory trust formed by PCEC to own interests in certain oil and gas properties in the Santa Maria Basin and the Los Angeles Basin in California (the “Underlying Properties”).
  • Any anticipated distribution is based, in part, on the amount of cash received or expected to be received by the Trust from PCEC with respect to the relevant period.
  • Any differences in actual cash receipts by the Trust could affect this distributable amount.